SAB Biotherapeutics Reports Q3 2026 Financial Results and Clinical Progress
SAB Biotherapeutics (SABS) reported a net loss of $22.3 million for the third quarter of 2026, a significant shift from the $45.4 million net income recorded in the same period last year. The company attributed the increased spending to higher research and development costs related to its SAFEGUARD study and expanded clinical headcount. Despite the loss, management maintains a strong liquidity position with $205 million in cash and investments, which is expected to fund operations through 2028. On the clinical front, the company achieved full enrollment for adult and adolescent cohorts in the SAFEGUARD trial and received FDA Fast Track designation for SAB-142 in treating new-onset Stage 3 type 1 diabetes. Topline data from the Phase 2b SAFEGUARD study is anticipated in the second half of 2027, while dosing for the PRISE study is expected to commence in the fourth quarter of 2026.
Tickers: $SABS